Clinical Trials Logo

Seborrheic Keratosis clinical trials

View clinical trials related to Seborrheic Keratosis.

Filter by:

NCT ID: NCT06108024 Recruiting - Clinical trials for Seborrheic Keratosis

A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Start date: November 6, 2023
Phase: Phase 2
Study type: Interventional

The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12-weeks post final application for a total of approximately 16-weeks of required participation in the study.

NCT ID: NCT06046144 Completed - Melanoma Clinical Trials

Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors

Micro3
Start date: November 2, 2022
Phase:
Study type: Observational

Reflectance confocal microscopy (RCM) is the reference in vivo imaging technique for identifying malignant melanocytic tumors prior to surgical excision. However, it is not widely used due to its high cost and highly technical and time-consuming nature. In addition to RCM, we currently use 2 less expensive dermatoscopes that also allow in vivo diagnosis: super-high magnification dermoscopy (D400) and Fluorescence-Advanced videodermatoscopy (FAV).

NCT ID: NCT05353374 Completed - Clinical trials for Seborrheic Keratosis

Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

A double-blind within person randomized controlled trial study was conducted on 90 wounds in 22 subjects. All wounds were randomized to receive either sodium fusidate ointment or petrolatum following cauterization.

NCT ID: NCT05136144 Active, not recruiting - Clinical trials for Seborrheic Keratosis

Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

This is a first-in-humans adaptive design open label trial to explore the safety and efficacy of SM-020. Multiple dosing cohorts will be enrolled. The first cohort will have a two-week treatment period of twice daily applications followed by a four-week follow-up period. Based on the results at any time from the first and subsequent cohorts, additional cohorts will explore different dosing regimens.

NCT ID: NCT04688749 Terminated - Melanoma (Skin) Clinical Trials

Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage

DermaSense
Start date: July 17, 2019
Phase:
Study type: Observational

The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.

NCT ID: NCT04249115 Terminated - Skin Lesion Clinical Trials

Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study

Start date: February 5, 2019
Phase: N/A
Study type: Interventional

Primary study objective is to evaluate the optimization of Nano-Pulse Stimulation (NPS) energy settings for lesion clearance of Seborrheic Keratosis (SKs) from off-facial areas of healthy adults.

NCT ID: NCT04229277 Completed - Malignant Melanoma Clinical Trials

Fast Track Diagnosis of Skin Cancer by Advanced Imaging

Start date: September 9, 2019
Phase: N/A
Study type: Interventional

Aim of study: To collect data for a new image-guided diagnostic algoritm, enabling the investigators to differentiate more precisely between benign and malignant pigmented tumours at the bedside. This study will include 60 patients with four different pigmented tumours: seborrheic keratosis (n=15), dermal nevi (n=15), pigmented basal cell carcinomas (n=15), and malignant melanomas (n=15), these four types of tumours are depicted in Fig.1, and all lesions will be scanned by four imaging technologies, recruiting patients from Sept 2019 to May 2020. In vivo reflectance confocal microscopy (CM) will be used to diagnose pigmented tumours at a cellular level and provide micromorphological information5;6. Flourescent CM will be applied to enhance contrast in surrounding tissue/tumours. Optical coherence tomography (OCT), doppler high-frequency ultrasound (HIFU) and photoacustic imaging (also termed MSOT, multispectral optoacustic tomography) will be used to measure tumour thickness, to delineate tumours and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. Diagnostic accuracy will be statistically evaluated by comparison to gold standard histopathology

NCT ID: NCT03846531 Completed - Clinical trials for Seborrheic Keratosis

Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study

Start date: May 4, 2017
Phase: N/A
Study type: Interventional

The primary purpose of this trial is to evaluate Nano-Pulse Stimulation (NPS) to clear or remove Seborrheic Keratosis (SK) lesions from off-facial areas of healthy adult subjects.

NCT ID: NCT03487588 Completed - Clinical trials for Seborrheic Keratosis

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses

SK-FAN
Start date: March 21, 2018
Phase: Phase 4
Study type: Interventional

This study is an open-label study designed to evaluate subject's satisfaction after treatment of seborrheic keratoses with A-101 40%.

NCT ID: NCT03148691 Completed - Clinical trials for Seborrheic Keratosis

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

Start date: May 17, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.